This year's featured leaders illustrate medtech's ability to adapt and thrive in an ever-changing business environment.

Steve Halasey

November 1, 2007

2 Min Read
A Platform for Interventional Medicine

COVER STORY

Return to article:

Shifting into a Higher Gear

Since turning its attention to the cardiology applications of its technology, in 1997, Stereotaxis has focused the bulk of its time and energy on developing solutions for electrophysiologists, who use the company's ablation catheters to treat cardiac arrhythmias. But the remote magnetic navigation capabilities of the Stereotaxis system also offer potential for the delivery of therapies in a wide variety of related applications.

In recent years, Stereotaxis has begun to apply its platform technology to the delivery of wires that guide interventional cardiology procedures in the coronary and peripheral vasculature. In difficult anatomies, it can become problematic to deliver these guidewires manually.

Stereotaxis aims to create a new model for vascular intervention by bringing integrated information, computer-aided devices, and advanced networking into the vascular lab. Overall, the technology has already been effective in treating more than 2000 patients with cardiovascular disease, in addition to its more than 8000 electrophysiology procedures.

At this October's Transcatheter Cardiovascular Therapeutics conference in Washington, DC, Stereotaxis demonstrated some of its guidewire delivery solutions for patients with complex vascular problems. In three cases broadcast live at the symposium, physicians used the Stereotaxis magnetic navigation system to perform the following procedures.

  • Navigate guidewires down both branches of a bifurcated stenosis, where stents were then
        deployed.

  • Use recent computed tomography studies to create a 3-D roadmap of a chronic total
        occlusion (CTO), which enabled guidewire advancement, CTO lesion crossing, and therapy
        delivery.

  • Produce a 3-D vascular map that enabled successful navigation across a subclavian stenosis
        to permit stent deployment.

    In the last case, a previous two-hour conventional percutaneous intervention of the patient had been unsuccessful due to extremely complex vessel anatomy. But crossing the subclavian lesion was accomplished with a Stereotaxis 3-D vessel roadmap and magnetic guidewire in less than 10 seconds of wiring time.

    Stereotaxis is working to increase adoption of its platform among interventional cardiologists. The company hopes to make it the system of choice for the performance of coronary and peripheral interventions—including chronic total occlusions, challenging superficial femoral artery lesions, and critical limb ischemia—as well as cell therapy delivery, mitral valve repair, and other difficult structural heart procedures.

    Copyright ©2007 MX

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like